CN106581747A - Strontium-containing bone cement and preparation method - Google Patents
- ️Wed Apr 26 2017
CN106581747A - Strontium-containing bone cement and preparation method - Google Patents
Strontium-containing bone cement and preparation method Download PDFInfo
-
Publication number
- CN106581747A CN106581747A CN201611126004.XA CN201611126004A CN106581747A CN 106581747 A CN106581747 A CN 106581747A CN 201611126004 A CN201611126004 A CN 201611126004A CN 106581747 A CN106581747 A CN 106581747A Authority
- CN
- China Prior art keywords
- bone cement
- strontium
- powder
- bone
- strontium ranelate Prior art date
- 2016-12-08 Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002639 bone cement Substances 0.000 title claims abstract description 112
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 229910052712 strontium Inorganic materials 0.000 title claims abstract 4
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 title claims abstract 4
- 239000000843 powder Substances 0.000 claims abstract description 44
- XXUZFRDUEGQHOV-UHFFFAOYSA-J strontium ranelate Chemical compound [Sr+2].[Sr+2].[O-]C(=O)CN(CC([O-])=O)C=1SC(C([O-])=O)=C(CC([O-])=O)C=1C#N XXUZFRDUEGQHOV-UHFFFAOYSA-J 0.000 claims abstract description 43
- 229940079488 strontium ranelate Drugs 0.000 claims abstract description 43
- 239000007788 liquid Substances 0.000 claims abstract description 33
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 17
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims abstract description 16
- 238000002347 injection Methods 0.000 claims abstract description 16
- 239000007924 injection Substances 0.000 claims abstract description 16
- 239000004342 Benzoyl peroxide Substances 0.000 claims abstract description 10
- 235000019400 benzoyl peroxide Nutrition 0.000 claims abstract description 10
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 claims abstract description 9
- 159000000007 calcium salts Chemical class 0.000 claims abstract description 9
- 229920000058 polyacrylate Polymers 0.000 claims abstract description 9
- 238000007711 solidification Methods 0.000 claims description 24
- 230000008023 solidification Effects 0.000 claims description 24
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical group [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 15
- 239000004568 cement Substances 0.000 claims description 14
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical group [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 claims description 12
- JOPDZQBPOWAEHC-UHFFFAOYSA-H tristrontium;diphosphate Chemical compound [Sr+2].[Sr+2].[Sr+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O JOPDZQBPOWAEHC-UHFFFAOYSA-H 0.000 claims description 12
- 150000005208 1,4-dihydroxybenzenes Chemical class 0.000 claims description 11
- 239000001506 calcium phosphate Substances 0.000 claims description 10
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 10
- 235000011010 calcium phosphates Nutrition 0.000 claims description 10
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 10
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 150000004992 toluidines Chemical class 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000000463 material Substances 0.000 abstract description 3
- 230000008439 repair process Effects 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 229920000642 polymer Polymers 0.000 abstract description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 abstract 2
- 230000010478 bone regeneration Effects 0.000 abstract 1
- GYVGXEWAOAAJEU-UHFFFAOYSA-N n,n,4-trimethylaniline Chemical compound CN(C)C1=CC=C(C)C=C1 GYVGXEWAOAAJEU-UHFFFAOYSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 description 14
- 230000006835 compression Effects 0.000 description 7
- 238000007906 compression Methods 0.000 description 7
- PYSOFCRZGINJKU-UHFFFAOYSA-N OC(=O)C=C.C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 Chemical compound OC(=O)C=C.C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 PYSOFCRZGINJKU-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 3
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 3
- 229910001928 zirconium oxide Inorganic materials 0.000 description 3
- 230000007547 defect Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000003519 biomedical and dental material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000001981 hip bone Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 230000002138 osteoinductive effect Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 206010041569 spinal fracture Diseases 0.000 description 1
- 229910001427 strontium ion Inorganic materials 0.000 description 1
- PWYYWQHXAPXYMF-UHFFFAOYSA-N strontium(2+) Chemical compound [Sr+2] PWYYWQHXAPXYMF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/16—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/025—Other specific inorganic materials not covered by A61L27/04 - A61L27/12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/12—Phosphorus-containing materials, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Transplantation (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention provides a strontium-containing bone cement and a preparation method. The bone cement consists of two parts, namely a powder body and liquid; the powder body comprises polyacrylate which contains benzoyl peroxide, a developing agent, calcium salt and strontium ranelate; the liquid comprises methacrylate which contains hydroquinone, N,N-dimethyl-p-toluidine and strontium ranelate; by adding the strontium ranelate to the bone cement, a methacrylate polymer which contains the strontium ranelate is generated, so that heat energy release when the bone cement is polymerized is relieved, curing temperature of the bone cement is reduced, injection performance of the bone cement is enhanced, sufficient operating time is offered to doctors and operating risks are reduced; with the addition of the strontium ranelate, the mechanical performance of the bone cement is improved, so that mechanical performance matching required by human body is relieved, and the biocompatibility and bone regeneration performance of the bone cement are enhanced; and the prepared bone cement, which is higher than 50MPa in compressive strength, can meet a demand of human body bone repair; therefore, the prepared bone cement is a bone repair material which is excellent in performance.
Description
Technical field
The present invention relates to a kind of strontium phosphate cement and preparation method, are mainly used in the fields such as bio-medical material.
Background technology
Acrylate bone cement is that it is by powder and liquid two parts group at present clinically using a kind of most bone cements Into.Powder main component is polyacrylate, barium sulfate, benzoyl peroxide (initiator, BPO), and liquid main component is first Base acrylate (MMA) monomer, N, N dimethyl para-totuidine and hydroquinones.Acrylate bone cement injection moldable and system Into arbitrary shape, mechanical strength is high, but while acrylate bone cement also having some limitations property, such as monomer have certain poison Property, biocompatibility is not good enough, and after injection human body degraded can not be absorbed, while it is without osteogenic action, Yi Song insecure with synosteosis It is dynamic, and the exothermic reaction in polymerization process is likely to result in nervous function damage etc..For bone cement polymerisation reactivity high temperature pair Surrounding tissue causes obvious fire damage, causes a series of complication such as local inflammation, necrosis, and many research reports are by changing Become bone cement self-characteristic, improve the method effectively prevention of bone cement correlation technique or mitigate bone cement fire damage.
Bone cement will not only reduce in use injury of the bone cement heat release to surrounding tissue, also keep bone cement to have Good biological nature.Calcium sulfate, calcium phosphate are good bioactive materials, and calcium sulfate solidification intensity is moderate, calcium phosphate tool There are good biologically active, biocompatibility and syringeability.Calcium sulfate, calcium phosphate are added in bone cement and are increased by many schemes Add biologically active, the biocompatibility of bone cement, but can not reduce or slow down the exothermic reaction of bone cement, do not reduce bone water The solidification temperature of mud.
Strontium Ranelate is mainly used in treating and preventing the osteoporosis of postmenopausal women, significantly reduces vertebral fracture and hipbone The danger that fracture occurs, can suppress in vivo the reabsorption of bone, the formation of bone can be promoted again, in vivo and in vitro with good life Thing activity, bioavilability and tolerance.
Strontium Ranelate with biologically active is added to the solidification temperature of reduction bone cement in bone cement in the present invention, by In the addition of Strontium Ranelate, partly it is polymerized with MMA, reduces the release of bone cement curing heat, and extends the solidification of bone cement Time, increase the heat release time of bone cement, reduce the accumulation of heat, reduce the solidification temperature of bone cement;Integration is solved What prior art was present can not reduce or slow down the exothermic reaction of bone cement, not reduce the problem of the solidification temperature of bone cement.
The content of the invention
It is an object of the invention to provide a kind of strontium phosphate cement and preparation method;For bone tissue reparation with low-heat The bone cement containing Strontium Ranelate of amount release.The present invention is added to Strontium Ranelate bone cement in bone cement, Strontium Ranelate Addition improves the curing performance of bone cement, extends the injection time of bone cement, reduces exothermic reaction and the solidification temperature of bone cement Spend, and Strontium Ranelate is added in bone cement, and strontium ion is discharged in vivo, induces bone cell growth, accelerates Cranial defect position Repair and treatment, for the research of related content of the present invention has no report.
Bone cement is made up of powder and liquid two parts, and powder main component is polyacrylate, calcium sulfate, calcium phosphate It is methacrylate Deng, liquid main component, Strontium Ranelate adds the hardening time for extending bone cement in the present invention, increases bone The injection property of cement, reduces the heat release of bone cement, improves the osteoinductive and mechanical property of bone cement.
Bone cement powder main component is the polyacrylate containing benzoyl peroxide, developer, it is also possible to containing calcium Salt, liquid main component is methacrylate, and the content of Strontium Ranelate is 0.01~2% in bone cement.
Bone cement concrete composition and weight/mass percentage composition are as follows:
Powder:
Polyacrylate 49~89% containing benzoyl peroxide;
Developer 10~30%;
Calcium salt 0~40%;
Strontium Ranelate 0.01~1%;
Liquid:
Methacrylate 94~99.9% containing hydroquinones;
N, N dimethyl para-totuidine 0.1~5%;
Strontium Ranelate 0~1%.
In bone cement powder, preferred size distribution is 1~100 μm of Strontium Ranelate powder;
Calcium salt is calcium phosphate, one kind of calcium sulfate or mixture, and when calcium salt content is 0, preparation is containing Strontium Ranelate Acrylate bone cement.
Developer is barium sulfate, zirconic one kind.
The preparation method of bone cement is according to following steps:
(1) Strontium Ranelate, the polyacrylate containing benzoyl peroxide, development are weighed according to the weight/mass percentage composition of powder Agent, calcium salt, are uniformly mixed to get bone cement powder;
(2) weigh Strontium Ranelate according to weight/mass percentage composition and be added to the methacrylate containing hydroquinones, N, N diformazans In base para-totuidine, bone cement liquid is mixed to get;
(3) according to powder liquid mass ratio 1~3:1, powder is added and is well mixed in liquid, solidification obtains strontium phosphate cement, Bone cement injection time is 5~12min.
It is an advantage of the current invention that:A small amount of Strontium Ranelate is added in bone cement, when bone cement is polymerized, Strontium Ranelate With methacrylate, the methacrylate polymers containing Strontium Ranelate are generated, reduce heat when bone cement is polymerized Release, reduces the solidification temperature of bone cement, extends the injection property of bone cement, gives doctor enough operating times, reduces Operation risk, and the heat release of bone cement is reduced, beneficial to scattering and disappearing for position heat is repaired, the accumulative of heat is reduced, reduce bone The solidification temperature of cement, greatly reduces infringement of the acrylate bone cement curing exotherm to human body, and the addition of Strontium Ranelate, changes The mechanical property of kind bone cement so as to be reduced to be matched with needed by human body mechanical property, increase bone cement biocompatibility and Osteanagenesis, and the compression strength of the bone cement for preparing meets the needs of human body Bone Defect Repari in more than 50MPa, is a kind of property The excellent bone renovating material of energy.
Description of the drawings
Fig. 1:The operation chart of bone cement;
Fig. 2:The solidification maximum temperature of bone cement, time comparison diagram;
Fig. 3:The mean compressive strength of bone cement.
Specific embodiment
Present disclosure is described in further detail with reference to embodiment, but embodiments of the present invention are not limited In this.
Embodiment 1
(1) weigh corresponding Strontium Ranelate (1%) according to the weight/mass percentage composition of powder, it is poly- containing benzoyl peroxide Acrylate (59%), barium sulfate (10%), calcium sulfate (15%) and calcium phosphate (15%), are uniformly mixed to get bone cement powder Body, common 20g;
(2) methacrylate (95%), N containing hydroquinones are measured, N dimethyl para-totuidine (5%), common 15g is obtained To bone cement liquid;
(3) according to powder liquid mass ratio 1.33:1, powder is added and is well mixed in liquid, solidification obtains strontium phosphate cement, Bone cement injection time is 12min.
Shown in operability as accompanying drawing 1-A, bone cement 3min injectables are used, and have the injection time of 12min, finally 20min solidifies, and compares with the not strontium phosphate cement of accompanying drawing 1-B, and the addition of Strontium Ranelate, the injection time of bone cement is prolonged by 6min Grow to 12min.
Requirement and the solidification temperature of method measure bone cement according to standard, from Fig. 2-C/D, the bone cement highest temperature Spend for 63 DEG C, hardening time 17min, 87 DEG C of the bone cement maximum temperature without Strontium Ranelate, hardening time 12min, Liang Zhexiang Relatively, add after Strontium Ranelate, the maximum temperature of bone cement differs 24 DEG C, and the release of bone cement heat is substantially reduced hardening time Extend 5min.
Requirement and the compression strength of method measure bone cement according to standard, sample is cylindric (Φ 6mm × 12mm), is resisted Compressive Strength mean value is 60.15Mpa (as shown in accompanying drawing 3-a).
Embodiment 2:
(1) weigh corresponding Strontium Ranelate (0.01%) according to the weight/mass percentage composition of powder, containing benzoyl peroxide Polyacrylate (49%), barium sulfate (30%), calcium sulfate (10.99%) and calcium phosphate (10%), are uniformly mixed to get bone water Mud powder, common 20g;
(2) weigh Strontium Ranelate (1%) and be added to methacrylate (94%), N containing hydroquinones, N dimethyl pair In toluidines (5%), it is well mixed and obtains bone cement liquid, common 10g;
(3) according to powder liquid mass ratio 2:1, powder is added and is well mixed in liquid, solidification obtains strontium phosphate cement, bone water Mud injection time is 9min.
Requirement and the solidification temperature of method measure bone cement according to standard, from Fig. 2-E, the bone cement maximum temperature For 66 DEG C, hardening time 16min.
Requirement and the compression strength of method measure bone cement according to standard, sample is cylindric (Φ 6mm × 12mm), is resisted Compressive Strength mean value is 65.32Mpa (as shown in accompanying drawing 3-b).
Embodiment 3
(1) weigh corresponding Strontium Ranelate (0.2%) according to the weight/mass percentage composition of powder, it is poly- containing benzoyl peroxide In acrylate (49.8%), barium sulfate (10%), calcium sulfate (30%) and calcium phosphate (10%), bone cement is uniformly mixed to get Powder, common 20g;
(2) weigh Strontium Ranelate (0.3%) and be added to methacrylate (96.9%), N containing hydroquinones, N diformazans In base para-totuidine (2.8%), it is well mixed and obtains bone cement liquid, common 20g;
(3) according to powder liquid mass ratio 1:1, powder is added and is well mixed in liquid, solidification obtains strontium phosphate cement, bone water Mud injection time is 12min.
Requirement and the solidification temperature of method measure bone cement according to standard, from Fig. 2-F, the bone cement maximum temperature For 59 DEG C, hardening time 19min.
Requirement and the compression strength of method measure bone cement according to standard, sample is cylindric (Φ 6mm × 12mm), is resisted Compressive Strength mean value is 52.55Mpa (as shown in accompanying drawing 3-c).
Embodiment 4
(1) weigh corresponding Strontium Ranelate (0.5%) according to the weight/mass percentage composition of powder, it is poly- containing benzoyl peroxide Acrylate (89%), zirconium oxide (10.5%), are uniformly mixed to get bone cement powder, common 20g;
(2) weigh Strontium Ranelate (0.2%) and be added to methacrylate (99.7%), N containing hydroquinones, N diformazans In base para-totuidine (0.1%), it is well mixed and obtains bone cement liquid, common 10g;
(3) according to powder liquid mass ratio 2:1, powder is added and is well mixed in liquid, solidification obtains strontium phosphate cement, bone water Mud injection time is 5min.
Requirement and the solidification temperature of method measure bone cement according to standard, from Fig. 2-G, the bone cement maximum temperature For 70 DEG C, hardening time 14min.
Requirement and the compression strength of method measure bone cement according to standard, sample is cylindric (Φ 6mm × 12mm), is resisted Compressive Strength mean value is 70.1Mpa (as shown in accompanying drawing 3-d).
Embodiment 5
(1) weigh corresponding Strontium Ranelate (0.3%) according to the weight/mass percentage composition of powder, it is poly- containing benzoyl peroxide Acrylate (67.7%), zirconium oxide (30%), calcium sulfate (2%) is uniformly mixed to get bone cement powder, common 21g;
(2) weigh Strontium Ranelate (0.2%) and be added to methacrylate (97.8%), N containing hydroquinones, N diformazans In base para-totuidine (2%), it is well mixed and obtains bone cement liquid, common 7g;
(3) according to powder liquid mass ratio 3:1, powder is added and is well mixed in liquid, solidification obtains strontium phosphate cement, bone water Mud injection time is 5min.
Requirement and the solidification temperature of method measure bone cement according to standard, from Fig. 2-H, the bone cement maximum temperature For 64 DEG C, hardening time 17min.
Requirement and the compression strength of method measure bone cement according to standard, sample is cylindric (Φ 6mm × 12mm), is resisted Compressive Strength mean value is 61.73Mpa (as shown in accompanying drawing 3-e).
Embodiment 6
(1) weigh corresponding Strontium Ranelate (0.2%) according to the weight/mass percentage composition of powder, it is poly- containing benzoyl peroxide Acrylate (55%), zirconium oxide (24%), calcium phosphate (20.8%) is uniformly mixed to get bone cement powder, common 20g;
(2) weigh Strontium Ranelate (0.6%) and be added to methacrylate (96.4%), N containing hydroquinones, N diformazans In base para-totuidine (3%), it is well mixed and obtains bone cement liquid, common 10g;
(3) according to powder liquid mass ratio 2:1, powder is added and is well mixed in liquid, solidification obtains strontium phosphate cement, bone water Mud injection time is 7min.
Requirement and the solidification temperature of method measure bone cement according to standard, from Fig. 2-I, the bone cement maximum temperature For 55 DEG C, hardening time 15min.
Requirement and the compression strength of method measure bone cement according to standard, sample is cylindric (Φ 6mm × 12mm), is resisted Compressive Strength mean value is 53.26Mpa (as shown in accompanying drawing 3-f).
Claims (5)
1. a kind of strontium phosphate cement, it is characterised in that bone cement is constituted and weight/mass percentage composition is as follows:
Powder:
Polyacrylate 49~89% containing benzoyl peroxide;
Developer 10~30%;
Calcium salt 0~40%;
Strontium Ranelate 0.01~1%;
Liquid:
Methacrylate 94~99.9% containing hydroquinones;
N, N dimethyl para-totuidine 0.1~5%;
Strontium Ranelate 0~1%.
2. bone cement as claimed in claim 1, it is characterised in that calcium salt is calcium sulfate, one kind of calcium phosphate or mixture, calcium When salt content is 0, preparation is the acrylate bone cement containing Strontium Ranelate.
3. bone cement as claimed in claim 1, it is characterised in that particle size distribution is 1~100 μm of thunder Buddhist nun in bone cement Sour strontium powder.
4. bone cement as claimed in claim 1, it is characterised in that developer is barium sulfate, zirconic one kind.
5. the preparation method of bone cement as claimed in claim 1, it is characterised in that the preparation of bone cement is according to following steps:
(1) according to the weight/mass percentage composition of powder weigh Strontium Ranelate, the polyacrylate containing benzoyl peroxide, developer, Calcium salt, is uniformly mixed to get bone cement powder;
(2) weigh Strontium Ranelate according to weight/mass percentage composition and be added to the methacrylate containing hydroquinones, N, N dimethyl pair In toluidines, bone cement liquid is mixed to get;
(3) according to powder liquid mass ratio 1~3:1, powder is added and is well mixed in liquid, solidification obtains low heat release bone containing strontium water Mud, bone cement injection time is 5~12min.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611126004.XA CN106581747A (en) | 2016-12-08 | 2016-12-08 | Strontium-containing bone cement and preparation method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611126004.XA CN106581747A (en) | 2016-12-08 | 2016-12-08 | Strontium-containing bone cement and preparation method |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106581747A true CN106581747A (en) | 2017-04-26 |
Family
ID=58597797
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611126004.XA Pending CN106581747A (en) | 2016-12-08 | 2016-12-08 | Strontium-containing bone cement and preparation method |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106581747A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113577369A (en) * | 2021-08-20 | 2021-11-02 | 山东明德生物医学工程有限公司 | Porous composite bone cement and preparation method thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2067494A1 (en) * | 2007-12-04 | 2009-06-10 | Charité-Universitätsmedizin Berlin | Sheet or tubular structure consisting of elastic biocompatible material and its use |
CN102256633A (en) * | 2008-12-19 | 2011-11-23 | 生物医药产业因苏布里股份有限公司 | Bone implant matrix and method of preparing the same |
CN104826170A (en) * | 2015-04-22 | 2015-08-12 | 山东明德生物医学工程有限公司 | Development bone cement and its preparation method and use |
CN104906632A (en) * | 2015-06-19 | 2015-09-16 | 上海凯利泰医疗科技股份有限公司 | Bone cement, and preparation method and application thereof |
CN105012995A (en) * | 2015-06-04 | 2015-11-04 | 武汉维斯第医用科技股份有限公司 | Collagen sponge containing bone-healing-promoting drug and preparation method thereof |
-
2016
- 2016-12-08 CN CN201611126004.XA patent/CN106581747A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2067494A1 (en) * | 2007-12-04 | 2009-06-10 | Charité-Universitätsmedizin Berlin | Sheet or tubular structure consisting of elastic biocompatible material and its use |
CN102256633A (en) * | 2008-12-19 | 2011-11-23 | 生物医药产业因苏布里股份有限公司 | Bone implant matrix and method of preparing the same |
CN104826170A (en) * | 2015-04-22 | 2015-08-12 | 山东明德生物医学工程有限公司 | Development bone cement and its preparation method and use |
CN105012995A (en) * | 2015-06-04 | 2015-11-04 | 武汉维斯第医用科技股份有限公司 | Collagen sponge containing bone-healing-promoting drug and preparation method thereof |
CN104906632A (en) * | 2015-06-19 | 2015-09-16 | 上海凯利泰医疗科技股份有限公司 | Bone cement, and preparation method and application thereof |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113577369A (en) * | 2021-08-20 | 2021-11-02 | 山东明德生物医学工程有限公司 | Porous composite bone cement and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2008230047B2 (en) | 2010-08-19 | One-component bone cement pastes and methods for curing them |
He et al. | 2015 | Bone cements for percutaneous vertebroplasty and balloon kyphoplasty: Current status and future developments |
US7138442B2 (en) | 2006-11-21 | Reduced exothermic bone replacement cement |
CN104826170B (en) | 2017-12-22 | A kind of developability bone cement and preparation method and purposes |
Nussbaum et al. | 2004 | The chemistry of acrylic bone cements and implications for clinical use in image-guided therapy |
CN106620841A (en) | 2017-05-10 | Low-temperature injectable acrylic resin bone cement and preparation method thereof |
CN104511054B (en) | 2016-05-11 | A kind of Anti-infective bone cement and preparation method thereof |
AU2009240850B2 (en) | 2013-10-24 | Polymethylmethacrylate bone cement composition for controlled hyperthermia treatment |
US9566216B2 (en) | 2017-02-14 | Bone cements containing magnetic calcium phosphate nanoparticles |
KR101851410B1 (en) | 2018-04-23 | Bone cement system for bone augmentation |
CN105031738B (en) | 2018-06-15 | A kind of low heat release bone cement and preparation method and application |
Yang et al. | 2017 | Synthesis and characterization of an injectable and hydrophilous expandable bone cement based on poly (methyl methacrylate) |
Quan et al. | 2023 | New research progress of modified bone cement applied to vertebroplasty |
CN106729974A (en) | 2017-05-31 | A kind of low temperature injectable acrylic resin bone cement and preparation method thereof |
Fisher et al. | 2015 | Hydroxyapatite‐reinforced in situ forming PLGA systems for intraosseous injection |
CN101530635B (en) | 2012-09-12 | Bioactive bone-repairing cement material |
CN106581747A (en) | 2017-04-26 | Strontium-containing bone cement and preparation method |
Robo et al. | 2021 | Long-term mechanical properties of a novel low-modulus bone cement for the treatment of osteoporotic vertebral compression fractures |
AU2016217493A1 (en) | 2017-08-10 | Ternary mixture for a bone cement and method for its realisation |
EP3122391A1 (en) | 2017-02-01 | Acrylic bone cement having a delayed release polymerization inhibitor such as an anti-oxidant for increased working time |
Dubey et al. | 2022 | Development of modified polymethyl methacrylate and hydroxyapatite (PMMA/HA) biomaterial composite for orthopaedic products |
Endogan et al. | 2009 | Effects of ingredients on thermal and mechanical properties of acrylic bone cements |
CN115645611B (en) | 2023-09-08 | High-strength self-expanding composite bone cement with osteogenic activity and preparation method thereof |
CN107899072A (en) | 2018-04-13 | It is a kind of can pore-forming the composite bone cement that can increase bone hold and its preparation method and application |
Hasandoost et al. | 2020 | Calcium sulfate‐containing glass polyalkenoate cement for revision total knee arthroplasty fixation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
2017-04-26 | PB01 | Publication | |
2017-04-26 | PB01 | Publication | |
2017-05-24 | SE01 | Entry into force of request for substantive examination | |
2017-05-24 | SE01 | Entry into force of request for substantive examination | |
2020-06-05 | RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170426 |
2020-06-05 | RJ01 | Rejection of invention patent application after publication |